Inhibition of allergic and non-allergic inflammation by phospholipase A2 inhibitors.
Tibes
U
U
Department of Preclinical Research, Boehringer Mannheim, Germany.
Vondran
A
A
Rodewald
E
E
Friebe
W G
WG
Schäfer
W
W
Scheuer
W
W
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000378:metabolism / Q000517:prevention & control*; D000001:Calcimycin / Q000494:pharmacology; D002351:Carrageenan / Q000633:toxicity; D016207:Cytokines / Q000096:biosynthesis; D004487:Edema / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D015777:Eicosanoids / Q000096:biosynthesis; D005246:Feedback; D007073:Immunoglobulin E / Q000276:immunology; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000502:physiology; D054467:Phospholipases A2; D051381:Rats
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D015777:Eicosanoids; D007073:Immunoglobulin E; D000001:Calcimycin; D002351:Carrageenan; D010741:Phospholipases A; D054467:Phospholipases A2